Introduction {#sec1}
============

Oestrogens are essential for reproductive function and fertility. They classically mediate their functions by binding to cognate oestrogen receptors, ERα and ERβ, encoded by the genes *ESR1* and *ESR2,* respectively. Oestrogens act via systemic endocrine signals and via local intracrine action to regulate key functional processes within the endometrium including proliferation, angiogenesis and inflammation ([@ref16]) that prime the endometrium for establishment and maintenance of pregnancy ([@ref15], [@ref17]). Oestrogen action is controlled by ligand availability but also via expression and localisation of ER isoforms which are altered in a cell and tissue context-dependent manner. We have previously used quantitative PCR (qPCR) and immunohistochemistry to document stage and cell-specific expression of ERα and ERβ, as well as ERβ splice variant isoforms in human endometrium and decidua of early pregnancy (reviewed in Gibson *et al*., 2012). Endometrial ERα expression is greatest in the proliferative phase with decreased expression in the secretory phase and a further reduction in first trimester decidual tissue compared to non-pregnant endometrial tissues ([@ref10]; [@ref28]). In those studies, we used a mouse monoclonal antibody directed against recombinant human ERα; the epitope for this antibody was not defined, but it recognised a protein of 66 kDa (consistent with full-length wild-type ERα) in breast cancer cell homogenates detected by western blot ([@ref7]) and detected ERα in both stromal and epithelial cells by immunohistochemistry ([@ref3]). In the studies by [@ref3], immunostaining for ERα detected a protein that was exclusively nuclear, which is consistent with the established functional role of this receptor protein as a ligand-activated transcription factor.

The human *ESR1* gene exhibits differential promoter usage and alternative splicing which give rise to splice variant isoforms of the receptor protein. ER46 was the first identified splice variant of human *ESR1* (initially designated hERα-46; ([@ref12])). The ER46 variant is a 46-kDa protein which lacks the N-terminal 173 amino acids of the full-length ERα protein (66 kDa, hereafter referred to as ER66) and arises from splicing of exon 1E to exon 2 via the E and F promoters ([@ref12]). ER46 contains both ligand-binding and DNA-binding domains and has been reported to bind oestradiol (E2) and to induce expression of oestrogen response element (ERE)-driven reporter genes ([@ref12]). ER46 and ER66 share identical sequence homology except that the N-terminal 173 amino acids of ER66 are absent in ER46. As all amino acids in ER46 are also present in ER66, there is no specific antibody that can uniquely identify ER46. It is therefore challenging to assess cell-specific patterns of native ER46 protein expression, and this has limited our understanding of its functional significance.

ER46 and ER66 proteins can be resolved by size using western blotting techniques in combination with ERα-specific antibodies that recognise epitopes in the N-terminus (ER66 alone) or C-terminus (ER66 and/or ER46) of the proteins. Using this approach, native expression of ER46 has been reported in human endothelial cell lines ([@ref26]) and in human peripheral blood leukocytes ([@ref31]). Detailed microscopy studies by Kim *et al*. using fluorescent tagged fusion protein revealed that ER46 can be detected localised to the plasma membrane in endothelial cells ([@ref20]). These studies have also demonstrated that membrane-associated ER46 can mediate rapid responses to oestrogens suggesting this receptor isoform may play a key role in 'non-genomic' or 'membrane-initiated' oestrogen receptor signalling ([@ref21]).

Uterine natural killer (uNK) cells are an abundant leukocyte population present in the endometrium during the late secretory phase and in the decidua of pregnancy and are characterised by high expression of the glycoprotein neural cell adhesion molecule (CD56) ([@ref6]; [@ref25]). They are abundant in perivascular and luminal regions of the endometrium and play key roles in regulating vascular remodelling in early pregnancy and during placentation ([@ref4]; [@ref34]). Dysregulation of uNK cell function has been implicated in disorders of pregnancy including pre-eclampsia, foetal growth restriction and recurrent pregnancy loss ([@ref13]; [@ref5]). However, the factors that regulate uNK cell function in both normal and pathological pregnancy remain poorly understood.

We have previously shown that isolated human uNK cells are exquisitely sensitive to oestrogens and can be stimulated to increase cell motility (chemokinesis and migration) in response to E2 ([@ref14]). Notably, changes in uNK cell motility in response to E2 are rapid, initiated within minutes and detected within 1 h of treatment, consistent with a possible non-genomic signalling response ([@ref14]). We demonstrated that the uNK cell response to E2 was abrogated in the presence of the ER antagonist ICI 182780 (fulvestrant) consistent with an ER-dependent mechanism ([@ref14]). We have previously characterised human uNK cells as ERα (ER66)-negative and ERβ-positive by immunohistochemistry and qPCR ([@ref19]; [@ref14]), but in those studies we did not consider expression of ER46 or its potential role in rapid responses to oestrogens.

In the current study, we used qPCR, western blot and multiplex immunohistochemistry to assess expression of ER46, ER66 and ERβ in human endometrial tissues and isolated uNK cells. We sought to identify cell populations within the endometrium that express ER46, define the cellular localisation of receptor proteins and investigate a potential functional role for ER46 in mediating oestrogen responses in uNK cells.

Materials and Methods {#sec2}
=====================

Human tissue samples {#sec3}
--------------------

Human endometrial tissues were obtained from women undergoing surgery for benign gynaecological conditions (*n* = 24) and human decidua samples from women undergoing surgical termination of pregnancy at a mean gestation of 10 weeks (*n* = 30). Local ethical committee approval was granted, and written informed patient consent was obtained prior to tissue collection by a dedicated research nurse (Ethical approval held by H.O.D.C.; LREC/05/51104/12 and LREC/10/51402/59). Tissue samples were fixed in 4% neutral buffered formalin or RNA Save (Geneflow, Staffordshire, UK). Stage of the menstrual cycle was determined histologically by an experienced gynaecological pathologist and by measurement of serum E2 and progesterone levels as previously detailed ([@ref3]). Primary human uNK cells were isolated from fresh human first-trimester decidua as described previously ([@ref14]). Briefly, decidual tissues (*n* = 18) were minced, digested in collagenase/DNAse and passed through 70- and 40-μm cell strainers. The cell suspension was overlaid on Histopaque 1077 (Sigma-Aldrich, Dorset, UK) to separate leukocytes. uNK cells isolated by magnetic-activated cell sorting, with magnetic bead separation using CD3 depletion and CD56 selection (Miltenyi Biotec, Germany). This process yielded a uNK cell population with \>98% purity ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}).

Ishikawa (human endometrial adenocarcinoma) cells (ECACC_99040201) which express ER66 were used as a positive control for western blotting and qPCR: cells were cultured according to established protocols ([@ref8]).

RNA extraction, cDNA synthesis and real-time qPCR {#sec4}
-------------------------------------------------

Total RNA was extracted from cell pellets or 20 mg of tissue using Tri-Reagent and chloroform, and homogenisation using a tissue lyser for 2 min at 20 Hz (Qiagen, Crawley, UK). RNA was extracted using RNeasy Mini kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. RNA quantity and purity were confirmed by NanoDrop ND-1000 spectrophotometry (NanoDrop Technologies, Wilmington, DE, USA) and was standardised to 100 ng/μl for all samples. cDNA was synthesised using the SuperScript VILO cDNA Synthesis kit (Invitrogen, Paisley, UK).

qPCR was performed with primer sets ([Supplementary Table SI](#sup6){ref-type="supplementary-material"}) designed using Roche Universal Probe Library Assay Design Center (Roche Diagnostics, UK) in conjunction with corresponding Fluorescein amidite-labelled probes. Briefly, a reaction mix was prepared containing 1× Express SuperMix, 200 nM of forward/reverse primer and 100-nM probe. Samples were assayed in duplicate, multiplexed with 18S (ribosomal RNA) labelled with VIC™ dye---TAMRA™ dye as internal control reference gene, and analysed on a 7900HT Fast Real-Time PCR machine (Applied Biosystems). Amplification was performed at 95°C for 10 min then 40 cycles of 95°C for 15 s and 60°C for 1 min. Target gene expression was assessed using the 2^−ΔΔCt^ method where the mean value of the proliferative samples (tissues) or Ishikawa cell homogenate (cell samples) was used for relative quantification after normalisation to reference gene 18S.

Protein extraction {#sec5}
------------------

Total protein from 30 mg of frozen tissue or cell pellets was extracted by homogenising in lysis buffer (1% Triton X-100, 167 mM NaCl, 5 mM EDTA (pH 8.5), 50 mM Tris (pH 7.5), 2 μg/ml Aprotinin and 1× Halt protease inhibitor cocktail (Thermo Fisher Scientific, Loughborough, UK) using a Tissue Lyser for 2 min at 20 Hz, followed by centrifugation at 9000*g* (Eppendorf 5414R) for 10 min at 4°C. Ishikawa cell nuclear protein fractions were extracted using Nuclear Extraction Kit (Active Motif, Belgium) according to the manufacturer's instructions. Protein quantification was performed using the DC protein Assay from Bio-Rad and read at 690 nm on a microplate spectrophotometer.

Western blot {#sec6}
------------

Western blotting was performed to identify ERα proteins corresponding to full-length (66 kDa) or truncated ERα (46 kDa). Proteins were separated on NuPAGE Novex 4--12% Bis--Tris polyacrylamide gels (Life Technologies Inc., Renfrew, UK) under reducing conditions with NuPAGE MOPS SDS running buffer then transferred onto Immobilon FL transfer membrane (EMD Millipore, Livingston, UK) using a semidry blotter for 90 min at 14 V. Membranes were incubated overnight at 4°C with primary antibodies: mouse anti-ERα 6F11 (1:300); mouse anti-ERα F-10 (1:1000); rabbit anti-ERβ (1:200); and loading controls were mouse anti-β-Tubulin (1:1000); mouse anti-β Actin (1:2000); and rabbit anti-β Actin (1:500), respectively ([Supplementary Table SII](#sup7){ref-type="supplementary-material"}). Membranes were washed in PBS containing 0.1% Tween-20, incubated with appropriate species-specific fluorescent-conjugated secondary antibodies ([Supplementary Table SIII](#sup8){ref-type="supplementary-material"}) and visualised using the Licor Odyssey infrared imaging system (Licor, Bad Homburg, Germany). Western blot densitometry was performed relative to loading control ([Supplementary Tables SIV](#sup9){ref-type="supplementary-material"}--[IX](#sup14){ref-type="supplementary-material"}). Uncropped gel data for endometrium, decidua and uNK cells are included in [Supplementary Figures S2](#sup2){ref-type="supplementary-material"}--[S4](#sup4){ref-type="supplementary-material"}.

Immunohistochemistry {#sec7}
--------------------

Tissues were sectioned and subjected to antigen retrieval in 0.01 M citrate pH 6 and immunohistochemistry performed according to standard methods ([@ref9]). Endogenous peroxidase was blocked by immersing slides in 3% (v/v) H~2~O~2~ in methanol for 30 min, and non-specific binding was blocked by incubating cells in normal goat serum/PBS/bovine serum albumin (NGS/PBS/BSA) for 30 min. Sections were incubated overnight with primary antibodies (as detailed in [Supplementary Table SII](#sup7){ref-type="supplementary-material"}) at 4°C followed by incubation with peroxidase-conjugated secondary antibody for 1 h ([Supplementary Table SIII](#sup8){ref-type="supplementary-material"}). Antigen detection was performed using Tyramide signal amplification (Perkin Elmer-TSA-Plus Fluorescein) according to the manufacturer's instructions. Negative controls, omitting the primary antibody, were included in each experiment.

For multiplex immunofluorescence experiments, steps were performed as above but with the inclusion of an elution step prior to repeating the staining protocol for subsequent primary antibodies by microwaving sections in 0.01 M citrate buffer (pH 6.0) for 150 s followed by cooling at room temperature for 20 min. Up to three primary antibodies were combined and distinguished using PerkinElmer-TSA-Plus-Fluorescein (Green), PerkinElmer-TSA-Plus-Cy3 (Red) and PerkinElmer-TSA-Plus-Cy5 (Blue). Slides were counterstained with DAPI and mounted with PermaFluor (Thermo Fisher Scientific, Loughborough, UK) prior to imaging.

![**Expression of oestrogen receptor isoforms in human endometrial tissues**. The expression of estrogen receptor *ESR1*, using N- and C-terminal primers, and *ESR2* was assessed using quantitative PCR (qPCR) in proliferative and secretory phase endometrium as well as first trimester decidua tissue samples. **(A)** N-terminal primers detected mRNAs encoding *ESR1* in all endometrial tissues: expression was unchanged between proliferative and secretory endometrial tissues and significantly decreased in decidua. **(B)** C-terminal primers detected mRNAs encoding *ESR1* in all endometrial tissues: expression was unchanged between endometrial tissues but mean expression of *ESR1* was greatest in secretory phase endometrial samples. **(C)***ESR2* was detected in all endometrial tissues. Tissues for qPCR analysis; proliferative, *n* = 4--5; secretory *n* = 18; decidua, *n* = 10. Kruskal--Wallis test with multiple comparisons. ^\*\*^*P* \< 0.01. All data are presented as mean ± s.e.m.](dez306f1){#f1}

Immunocytochemistry {#sec8}
-------------------

Isolated uNK cells were cultured in coated BD Falcon Chamber slides (BD Bioscience, Wokingham, UK) and washed twice with PBS at room temperature. Cells were fixed in ice cold methanol for 20 min, washed and permeabilised in a solution containing 0.2% IGEPAL (Sigma Aldrich, Dorset, UK), 1% BSA and 10% NGS diluted in PBS for 20 min at room temperature. Endogenous peroxidase was blocked by immersing slides in 0.15% (v/v) H~2~O~2~ in methanol for 30 min, and non-specific binding was blocked by incubating cells in NGS/PBS/BSA for 30 min. Cells were incubated with primary antibody overnight, followed by incubation with peroxidase-conjugated secondary antibody for 1 h ([Supplementary Table SIII](#sup8){ref-type="supplementary-material"}), and finally Tyramide signal amplification was performed according to the manufacturer's instructions. Slides were counterstained with DAPI and mounted in PermaFluor prior to imaging.

Imaging {#sec9}
-------

Fluorescent images were acquired with a Zeiss LSM 710 Confocal microscope and processed with ZEN 2009 Software (Zeiss).

Live cell imaging {#sec10}
-----------------

The chemokinesis of uNK cells was assessed as described previously ([@ref14]). Isolated uNK cells were suspended in a collagen matrix in Ibidi μ-Slide Chemotaxis 3D chamber slides (Ibidi, 80326, supplied by Thistle Scientific Ltd, Uddingston, UK). Chamber slides were set up containing serum-free phenol red-free RPMI 1640 media and treatment. Cells were isolated from two different primary patient decidua tissues and set up in separate chambers for each patient and treatment. The response to the membrane-impermeable ligand E2-BSA (10 nM equivalent), the ERβ-selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN; 10 nM) or dimethylsulphoxide (DMSO) vehicle control was measured using time-lapse microscopy. Cells were imaged every 2 min for 2 h using an Axiovert 200 Inverted Fluorescent Microscope (Zeiss). Data were analysed using ImageJ (manual cell tracking plug-in; <http://rsb.info.nih.gov/ij/plugins/track/track.html>) and Ibidi 'chemotaxis and migration tool' software (Ibidi, Gräfelfing, Germany). Individual cells were tracked across the time course; *n* = 38 cells per patient per treatment.

Statistics {#sec11}
----------

Statistical analysis was performed using GraphPad Prism (San Diego, CA, USA). Kruskal--Wallis test with Dunn's multiple comparison test was used to determine significance between treatments. Where data were analysed as fold change, significance was tested using the one-sample Student's *t* test with hypothetical mean of 1. Criterion for significance was *P* \< 0.05. All data are presented as mean ± SEM.

Results {#sec12}
=======

Profiling human endometrial tissues reveals distinct patterns of ER isoform expression {#sec13}
--------------------------------------------------------------------------------------

Due to the overlapping sequence homology between mRNAs encoding full-length ERα (ER66) and the truncated splice variant isoform ER46, it is impossible to design oligonucleotide primers that can uniquely distinguish between the two isoforms. In this study, we designed primer pairs ([Supplementary Table SI](#sup6){ref-type="supplementary-material"}) directed against sequences in the N or C terminal of the receptor and used these to detect mRNAs for either ER66 alone (N-terminal primers) or ER66 and/or ER46 (C-terminal primers). MRNAs encoded by *ESR1* assessed using N-terminal primers were present in endometrial tissue homogenates from proliferative and secretory phase endometrium ([Fig. 1A](#f1){ref-type="fig"}) and at significantly decreased levels in decidual tissue homogenates compared to endometrium in both phases (*P* \< 0.01). In contrast, mRNA expression of *ESR1* assessed using C-terminal primers was detected in all samples, and mean expression was greatest in secretory phase endometrium ([Fig. 1B](#f1){ref-type="fig"}). MRNAs encoded by *ESR2* (detected using primers directed against the wild type isoform, ERβ1) were detected in proliferative and secretory phase endometrium as well as decidua ([Fig. 1C](#f1){ref-type="fig"}).

![**Protein expression of ER isoforms in human endometrial tissues**. Protein expression of ER isoforms in endometrial tissue homogenates (proliferative phase *n* = 4; secretory phase *n* = 4, decidua *n* = 8) was assessed by western blot using the ERα 6F11 or the C-terminal-specific ERα F-10 antibodies and an antibody that detected ERβ. **(A)** Protein expression of ER isoforms ER66 (6F11 antibody band), ER46 (F-10 antibody band) and ERβ was assessed by densitometry analysis in endometrium (**A**; proliferative samples denoted by circles, secretory phase samples by triangles) and decidua (**B**; squares) and normalised to loading control. All isoforms were present in endometrial tissues (pooled proliferative and secretory), but ER46 (*P* \< 0.0001) and ERβ (*P* \< 0.05) protein concentrations were significantly greater than ER66 in decidual tissues. **(C)** In non-pregnant endometrial tissues, full-length ERα was detected at a band corresponding to 66 kDa (red) with the ERα 6F11 antibody. The C-terminal ERα F-10 antibody detected two bands in non-pregnant endometrial tissue homogenates corresponding to 66 and 46 kDa (green). ERβ was detected at a band corresponding to 59 kDa (red). **(D)** In first trimester decidua tissue homogenates, full-length ERα was not detected with the ERα 6F11 antibody but was present in Ishikawa cell control homogenate (Ish) at a band corresponding to 66 kDa (red). Only the 46-kDa band was detected in decidua tissue homogenates using the ERα F-10 antibody (green). ERβ was detected at a band corresponding to 59 kDa (red). ER antibodies, band sizes and loading controls (actin or B-tubulin (Btub)) as indicated. AU---arbitrary units. ^\*^*P* \< 0.05. ^\*\*\*\*^*P* \< 0.0001. Kruskal--Wallis test with multiple comparisons. Data are presented as mean ± s.e.m.](dez306f2){#f2}

We next assessed protein expression of ER46 and ER66 isoforms by performing western blotting using antibodies directed against either the whole receptor (clone 6F11) or an epitope in the C-terminal domain (clone F-10) of ERα. Densitometry measurements identified variation in the abundance of ER proteins ([Fig. 2A](#f2){ref-type="fig"} and [B](#f2){ref-type="fig"}); endometrial tissues expressed all three proteins. In decidua ER66 was not detected and expression of ER46 (*P* \< 0.001) and ERβ1 (*P* \< 0.05) was significantly greater than ER66. A single protein band (\~66 kDa) was detected in endometrial tissue homogenates using the ERα 6F11 antibody: decidual tissue homogenates had no detectable protein at this size ([Fig. 2C](#f2){ref-type="fig"} and [D](#f2){ref-type="fig"}). Using the C-terminal-specific ERα F-10 antibody, proteins corresponding to both 46 and 66 kDa were detected in endometrium ([Fig. 2C](#f2){ref-type="fig"}) but only a 46-kDa protein was detectable in decidua ([Fig. 2D](#f2){ref-type="fig"}). A single 59-kDa band corresponding to full-length ERβ1 ([@ref10]) was detected in all samples ([Fig. 2C](#f2){ref-type="fig"} and [D](#f2){ref-type="fig"}).

![**Immunostaining of ER isoforms in human endometrial tissues.** The expression and localisation of ER proteins in endometrial tissues was assessed using multiplex immunohistochemistry. The ERα 6F11 (green) or the C-terminal-specific ERα F-10 antibodies (red) identified either ER66 or both ER66 and ER46, respectively. In proliferative phase endometrial biopsies, the expression of both antibodies co-localised and was detected in the nuclei of all cells (inset; yellow arrows). In secretory phase endometrial biopsies, strong nuclear staining for ER66 was detected using the ERα 6F11 antibody in both stromal and epithelial cells (arrowhead; green), and co-localisation of both antibodies was detected in the nuclei of some stromal cells (yellow arrow). Extra-nuclear expression of ERα (putatively ER46) was detected in the cytoplasm of epithelial and stromal cells (red) and was localised to the membrane of some cells within the stromal compartment which did not express ER66 (putative immune cells; white arrow). In decidua tissues, extra-nuclear expression of ERα (F-10 ERα antibody; putatively ER46) was detected in the cytoplasm of stromal cells (red; arrowhead) and was localised to the membrane of putative immune cells which did not express ER66 (white arrow). Some nuclear expression of ER66 was detected using by the ERα 6F11 antibody in stromal cells (green) and co-expression of both antibodies was detected in the nuclei of stromal cells (yellow arrow). Dashed box indicates cropped zoom region. Images are representative of at least three different patient samples per tissue type. Scale bars 20 μm, nuclear counterstain DAPI (grey).](dez306f3){#f3}

Immunostaining of ER isoforms in human endometrial tissues {#sec14}
----------------------------------------------------------

Dual immunohistochemistry was performed in endometrial tissues to assess the pattern of localisation of proteins recognised by the 6F11 and F-10 ERα antibodies. Presence of ER46 was inferred from staining observed using the C-terminal ERα F-10 antibody and absence of staining with the ERα 6F11 antibody. In proliferative phase endometrium ([Fig. 3](#f3){ref-type="fig"}), ERα was detected with both the ERα 6F11 antibody (green) and C-terminal ERα F-10 antibody (red). As expected, expression of ER66 was detected in nuclei of both stromal and epithelial cells (yellow arrows). In contrast, a divergent pattern of expression was observed in secretory phase tissue ([Fig. 3](#f3){ref-type="fig"}; 'secretory'). ER66 detected using the ERα 6F11 antibody (green) was localised exclusively to cell nuclei and detected in all epithelial cells and some stromal cells. Positive staining using the C-terminal ERα F-10 antibody (ER46/66, red) was detected in the nuclei of epithelial and stromal cells and overlapped with ERα 6F11 antibody (yellow arrow). However, C-terminal ERα F-10 antibody (red) also localised to extra-nuclear sites and was detected in the cytoplasm of epithelial and stromal cells (white arrowhead) as well as the membrane of some cells (white arrows). Notably, when protein was localised to the membrane, no staining was detectable in the nucleus using either antibody (white arrows; secretory endometrium and decidua [Fig. 3](#f3){ref-type="fig"}). This pattern of expression was most obvious in first trimester decidual tissues, which express lower concentrations of ER66 ([Figs. 1A](#f1){ref-type="fig"} and [2B](#f2){ref-type="fig"}). Cytoplasmic expression of ERα was detected using the C-terminal ERα F-10 antibody (red) in decidualised stromal cells (white arrowhead; decidua [Fig. 3](#f3){ref-type="fig"}), and membrane expression was apparent on numerous cells within the stromal compartment (white arrow; decidua [Fig. 3](#f3){ref-type="fig"}).

Human uNK cells express ER46 in first-trimester decidual tissues {#sec15}
----------------------------------------------------------------

As CD56-positive uNK cells are the most abundant leukocyte in first trimester decidual tissues (([@ref6]), [Supplementary Fig. S5](#sup5){ref-type="supplementary-material"}), we investigated whether membrane ERα expression was associated with this cell by performing triple immunohistochemistry using the 6F11 and ERα F-10 antibodies and anti-CD56 ([Fig. 4](#f4){ref-type="fig"}). Co-staining of ERα 6F11 antibody (green) confirmed our previous finding that CD56-positive cells (blue) were ER66-negative ([Fig. 4](#f4){ref-type="fig"}). In contrast, ERα was detected on the membranes of uNK cells using the C-terminal ERα F-10 antibody (red): this co-expression is visible as pink staining on the surface of uNK cells (white arrows; [Fig. 4](#f4){ref-type="fig"}).

![**Expression of ER46 in decidual uNK cells.** The expression and localisation of ER proteins in uterine natural killer (uNK) cells was assessed in decidua tissues using multiplex immunohistochemistry. The ERα 6F11 (green) or the C-terminal-specific ERα F-10 antibodies (red) and the uNK cell marker CD56 (blue) were assessed. uNK cells were abundant in decidua and staining for surface marker CD56 (blue) co-localised with membrane staining for ERα (red) identified using the ERα F-10 antibody (ER46; white arrows) but were negative for ER66. ERα identified using the ERα F-10 antibody was also detected in the cytoplasm of stromal cells and weakly in stromal nuclei (red, white arrowhead). Some nuclear staining for ER66 was detected using the ERα 6F11 antibody in stromal cells (green) which co-expressed ER46 detected with ERα F-10 antibody staining (yellow arrow). Images are representative of staining from at least three different patient samples. Dashed box indicates cropped zoom region. Scale bars 50 μm, nuclear counterstain DAPI (grey).](dez306f4){#f4}

Expression of ER46 in isolated human uNK cells {#sec16}
----------------------------------------------

uNK cells were isolated from decidua by magnetic sorting, and expression of ER66, ER46 and ERβ1 was assessed by qPCR, western blot and immunocytochemistry ([Fig. 5](#f5){ref-type="fig"}). Consistent with our previous studies, mRNAs detected using N-terminal primers (ER66) were significantly lower in uNK cells than Ishikawa cells (*P* \< 0.0001); in contrast, mRNAs detected using C-terminal-specific primers were significantly higher in uNK cells ([Fig. 5A](#f5){ref-type="fig"}; *P* \< 0.05). Expression of ER46 in isolated uNK cells was confirmed by western blot ([Fig. 5B](#f5){ref-type="fig"}) and immunofluorescence with staining localised to the cell membrane ([Fig. 5C](#f5){ref-type="fig"}). Consistent with our previous findings, uNK cells contained mRNAs encoded by *ESR2* as well as protein of 59 kDa on western blots corresponding to full-length ERβ1 protein ([Fig. 5A](#f5){ref-type="fig"} and [B](#f5){ref-type="fig"}).

![**Isolated uNK cells express ER46 and increase cell motility in response to E2-BSA.** UNK cells were isolated from decidua tissues by magnetic cell sorting using the magnetic-activated cell sorting system. The expression of ER isoforms was assessed by qPCR, western blot and immunofluorescence. **(A)** Primers that mapped to either the N- (\'ER66\') or C-terminal (\'ER46\') of *ESR1*, or *ESR2* (ERbeta) were used to assess mRNA expression in uNK cells relative to Ishikawa cell control lysates. The expression of mRNAs encoding the N-terminal of *ESR1* was significantly reduced in uNK cells compared to Ishikawa control (*P* \< 0.0001). In contrast, the expression of mRNAs encoding the C-terminal of *ESR1* and *ESR2* were significantly increased in uNK cells compared to Ishikawa control (*P* \< 0.01). **(B)** Protein expression was assessed by western blot in cell lysates of isolated uNK cells. ERα protein was assessed using the F-10 ERα antibody and a 46-kDa band was detected in uNK cells. No corresponding 66-kDa band was detected in uNK cells but was present in Ishikawa control lysate (Ish). ERβ was detected in both uNK cells and Ishikawa control by western blot. **(C)** Direct immunofluorescence was performed on isolated uNK cells using the F-10 ERα antibody and expression of ER46 was confirmed. Live cell imaging of isolated uNK cells was performed to assess cell motility in response to either vehicle control (dimethylsulphoxide: DMSO), a membrane impermeable form of E2 (17β-oestradiol conjugated to bovine serum albumin: E2-BSA) or the ERβ selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN). **(D)** E2-BSA significantly increased uNK cell velocity compared to vehicle control (DMSO; *P* \< 0.0001) and DPN (*P* \< 0.001). **(E)** E2-BSA significantly increased the accumulated distance of uNK cells compared to vehicle control (DMSO; *P* \< 0.0001) and DPN (*P* \< 0.001). DPN did not have an independent impact on either velocity or accumulated distance of uNK cells. ER antibodies and band sizes as indicated, loading controls B-actin or B-tubulin as indicated. Scale bars 5 μm, nuclear counterstain DAPI (grey). ^\*^*P* \< 0.05, ^\*\*\*^*P* \< 0.001, ^\*\*\*\*^*P* \< 0.0001. Samples and analysis---qPCR: uNK cells, *n* = 5; Ishikawa *n* = 7; One-sample Student's *t* test with hypothetical mean of 1. Western blot: uNK cells, *n* = 6. Cell motility analysis: *n* = 76 per treatment, Kruskal--Wallis test with multiple comparisons. All data are presented as mean ± s.e.m.](dez306f5){#f5}

ER46 expression in uNK cells promotes membrane-initiated changes in cell motility {#sec17}
---------------------------------------------------------------------------------

We have previously demonstrated that treatment of isolated uNK cells with E2 results in increased rates of cell migration ([@ref14]). Based on receptor expression profiling described above, we investigated whether the impact of E2 on uNK cells could be mediated by ER46 (membrane) or ERβ (nucleus). Cells were treated with E2-BSA (which cannot cross the cell membrane and would putatively activate ER46), DPN (ERβ-selective agonist) or DMSO (vehicle control). We performed live cell imaging of uNK cells using time-lapse microscopy and assessed cell motility. E2-BSA significantly increased uNK cell velocity compared to both DMSO (*P* \< 0.0001) and DPN (*P* \< 0.001) ([Fig. 5D](#f5){ref-type="fig"}). Mean velocity of DPN-treated cells was slightly greater than DMSO, but this was not statistically significant. Similarly, E2-BSA significantly increased the accumulated distance of uNK cells compared to both DMSO (*P* \< 0.000 1) and DPN (*P* \< 0.001) ([Fig. 5E](#f5){ref-type="fig"}). DPN did not have an independent effect on uNK cell accumulated distance within 2 hours of incubation.

Discussion {#sec18}
==========

Oestrogens are essential regulators of endometrial function and fertility. Expression of the ER splice variant ER46 has been demonstrated in peripheral blood leukocytes and isolated endothelial cells. In the current study, we have shown for the first time that expression of ER46 in the human endometrium is distinct from that of full-length ERα (ER66). Notably, ER46 is uniquely expressed on the membrane of uNK cells, which are otherwise ER66-negative. Functional analysis of uNK cells demonstrated that targeting of ER46 with E2-BSA increased cell motility via rapid, putatively non-genomic mechanisms.

Expression of ER46 has not previously been described in human endometrial tissues; however, by using antibodies able to distinguish between this variant and full-length ER66, we identified ER46 protein in tissue homogenates from both cycling (non-pregnant) endometrium as well as first-trimester decidua. Previous studies have reported that ER46 acts as a dominant negative repressor of ER66, inhibiting E2-induced transcription of a reporter gene and cell proliferation ([@ref26]; [@ref30]). We suggest that expression of ER46 is most likely to impact on classical responses to ER ligands in the endometrium during the proliferative phase when ER46 and ER66 were both detected in the nuclei of endometrial cells ([Fig. 3](#f3){ref-type="fig"}). In secretory phase and decidua tissue samples, immunohistochemistry demonstrated that ER46 was most abundant in the cytoplasm, whereas ER66 was exclusively nuclear. Thus, fewer positive cells were detected in which both ER46 and ER66 isoforms were co-localised to cell nuclei. This change in cellular localisation of ER46 indicates that ER46/ER66 interactions may differ across the menstrual cycle. Further studies are needed to assess whether ER46/ER66 dimerisation can impact on the regulation of endometrial function in response to E2. This may be particularly relevant to the pathophysiology of endometrial hyperplasia/cancer where oestrogens are key drivers of epithelial proliferation and cancer growth ([@ref8]; [@ref35]).

uNK cells are the predominant leukocyte in secretory endometrium and first-trimester decidua where they mature to acquire phenotypic properties that distinguish them from their peripheral blood (pb) NK cell precursors ([@ref23]; [@ref29]; [@ref22]). Notably, uNK cells are transcriptionally distinct from pbNK cells ([@ref25]), and they exhibit decreased cytotoxicity and increased cytokine secretion compared to pbNK cell subsets. This phenotype is critical to their function as they are essential mediators of vascular remodelling in early pregnancy ([@ref34]). Accumulating evidence supports a role for oestrogens in controlling the function of both pbNK precursors and their uNK cell descendants within the endometrium. Human pbNK cells are ER-positive with evidence for ERα and ERβ expression ([@ref31]). Profiling of human pbNK cells isolated from different phases of the menstrual cycle demonstrated that pbNK cells exhibit increased adhesion on Day 14 (when E2 concentrations peak in the circulation) compared to other phases of the cycle. In the same study, E2 treatment *in vitro* increased adhesion of pbNK cells to uterine tissues sections ([@ref37]). NK cells play a crucial role in defence against pathogens by carrying out cell-mediated toxicity. This function also appears to be regulated by oestrogens in women as NK cell activity, measured by lytic effector function, is reported to be increased in postmenopausal women (low circulating E2) compared to premenopausal women. Furthermore, NK cell activity is decreased in postmenopausal women following oestrogen hormone replacement therapy ([@ref1]). This effect is also mirrored in mouse splenic NK cells where E2 is reported to decrease cytotoxic activity ([@ref11]) and their proliferative capacity ([@ref18]). Thus, bioavailability of E2 appears to have impacts on homing of pbNK cells to the uterus and also to promote a low cytotoxicity phenotype that is similar to uNK cells. The oestrogen-dominated microenvironment found in the endometrium in early pregnancy is therefore likely to contribute to a similar functional adaptation of uNK cells within the tissue ([@ref15]).

We previously demonstrated that incubation with E2 increases uNK cell motility ([@ref14]), attributing the impact of E2 to signalling via ERβ1 as we failed to detect any ERα (ER66) in these cells. However, the changes in uNK cell motility detected in response to E2 were rapid (within 1 h in ([@ref14])), which prompted us to consider a role for ER46 and membrane-initiated signalling as a mechanism to explain these changes in uNK cell function. Cells which express ER46 may be more likely to transduce oestrogenic responses via cell membrane-initiated pathways. For example, in ER-negative COS7 cells in which expression of either ER46 or ER66 was induced, ER46 was found to be less efficient at inducing transcription of an ERE-reporter construct than ER66 but more efficient at inducing membrane-initiated phosphorylation of endothelial nitric oxide synthase ([@ref26]). ER46 has been located to the cell membrane of peripheral blood leukocytes and is reported to be the only ER isoform detected in the membrane of pbNK cells ([@ref31]). Stimulation of activated human pbNK cells with E2-BSA is reported to increase secretion of interferon-γ ([@ref31]). In the current study, we have detected ER46 protein on the cell membrane of decidual uNK cells and found that incubation with E2-BSA, but not the ERβ1-selective agonist DPN, rapidly increased cell motility, consistent with ER46-mediating membrane-initiated rapid responses to oestrogens. We have previously demonstrated that oestrone (E1) and E2 are secreted by decidualised stromal cells ([@ref15]), which may account for accumulation of uNK cells in perivascular areas of the endometrium ([Fig. 4](#f4){ref-type="fig"}, [Supplementary Fig. S5](#sup5){ref-type="supplementary-material"}) where they promote vascular remodelling in early pregnancy ([@ref34]; [@ref14]). Changes in uNK cell motility via ER46 may therefore be required for appropriate control of spatiotemporal remodelling during the establishment of pregnancy.

It is possible that expression of other ERs, such as ER36 (36 kDa ER isoform) or G protein-coupled ER (GPER), may mediate membrane-initiated responses to oestrogens in endometrial cells as both receptors have been detected at the cell membrane ([@ref36]; [@ref38]; [@ref39]). However, to the best of our knowledge neither receptor has been detected in uNK cells. Furthermore, ER36 expression has not been reported in the endometrium and the receptor protein lacks both transcriptional activation domains (AF-1 and AF-2) ([@ref38]) and cannot bind E2 ([@ref27]). Whilst GPER has been detected in endometrial tissues, its expression appears higher in proliferative than secretory phase or decidua and it has been localised to epithelial cells ([@ref24]; [@ref32]). This pattern contrasts with the abundant expression of ER46 in multiple cell types in endometrium and decidua reported in the current study. Although GPER binds E2, it does not bind other endogenous oestrogens, such as E1 or oestriol ([@ref36]), and drugs that inhibit activation of nuclear ERs, including ICI 182780, function as full agonists to GPER ([@ref33]). Given the results in our previous studies demonstrating that *both* E1 and E2 increase uNK cell migration and that these effects are abrogated by ICI 182780, it is unlikely that GPER is responsible for this rapid change in cell function.

In the current study, a further band was weakly detected by western blot using the ERα F-10 antibody (\~50 kDa) but only in endometrial tissue homogenates ([Fig. 2C](#f2){ref-type="fig"}). This may represent non-specific binding on the immunoblot, or it is possible based on the apparent size that this band relates to ERα isoform 2 (53 kDa). The sequence of this isoform differs from the canonical ER66 sequence and is missing amino acids 255--366 which contain the ligand-binding domain. Given that we did not detect this band in decidua tissue homogenates or in isolated uNK cells and that ERα isoform 2 lacks the ligand binding domain, we conclude that this isoform did not affect E2-dependent regulation of uNK cells.

Conclusion {#sec19}
==========

In the present study, we provide new evidence for expression of human ER46 in the human endometrium and decidua and highlight a role for this isoform in oestrogenic regulation of uNK cell function. Given the importance of uNK cells to regulating vascular remodelling in early pregnancy and the potential for selective targeting of ER46, this may be an attractive future therapeutic target in the treatment of reproductive disorders.
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